ScaleReady and CTMC, a joint venture between National Resilience and MD Anderson Cancer Center, have partnered to help lessen the manufacturing barriers holding back life-saving cell and gene therapies (CGTs) from reaching more patients by integrating automation tools.
The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilising the Fresenius Kabi Lovo(R) and Cue(R) cell processing systems.
“ScaleReady’s expertise and platform access will help us to leverage innovative technologies, like the Lovo, for our cell therapy process,” said Laine Linden, Head of CTMC Technical Operations. “With the addition of the Fresenius Kabi Cue to our manufacturing platform, we hope to drive down variability and increase the number of patients we can successfully treat by automating and closing the final fill and finish steps of our cell therapy products.”
